 |
Top 10 Startups developing Cancer Vaccines
Updated: April 14, 2024 |
Cancer vaccines are a promising avenue of research that aims to prevent or treat cancer by stimulating the body's immune response against cancer cells. These vaccines hold the potential to revolutionize cancer treatment by offering a targeted and personalized approach to fighting this devastating disease.
1
Country: Germany | Funding: $1.7B
We are developing the next generation of personalized immunotherapies to help revolutionize the treatment of people with cancer and other debilitating diseases.
We are developing the next generation of personalized immunotherapies to help revolutionize the treatment of people with cancer and other debilitating diseases.
2
Country: USA | Funding: $222.3M
Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer.
Elicio Therapeutics is a pharmaceutical research company that develops an immuno-tumor vaccine to treat cancer.
3
Country: Denmark | Funding: $175M
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines.
IO Biotech ApS is a clinical stage biotech company developing disruptive immune therapies i.e. checkpoint/cancer vaccines.
4
Country: Australia | Funding: A$80M
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
Imugene is a publicly-listed biotechnology company with operations in America and Europe,
5
Country: USA | Funding: $75.4M
Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines.
Immunomic Therapeutics is a development stage biotechnology company that develops lysosomal associated membrane protein-based vaccines.
6
Country: USA | Funding: $34.3M
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology.
7
Country: Norway | Funding: NOK270M
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.
Ultimovacs is a pharmaceutical company developing novel immunotherapies against cancer.
8
Country: South Korea | Funding: ₩27B
Aston Sci is a clinical-stage biopharmaceutical company that develops medicines in oncology, immunology, and geriatrics. It's cancer vaccine is being evaluated for breast and gastric cancer
Aston Sci is a clinical-stage biopharmaceutical company that develops medicines in oncology, immunology, and geriatrics. It's cancer vaccine is being evaluated for breast and gastric cancer
9
Country: UK | Funding: £15.7M
Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body’s own immune system.
Scancell is focused on developing innovative immunotherapies for cancer that stimulate the body’s own immune system.
10
Country: USA | Funding: $6.8M
BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma and ovarian cancer.
BioVaxys is a clinical stage biotechnology company developing immunotherapeutic cancer vaccines targeting melanoma and ovarian cancer.
11
Country: UK | Funding: $3M
VacV Biotech develops an oncolytic virus platform based on the vaccinia virus.
VacV Biotech develops an oncolytic virus platform based on the vaccinia virus.
12
Country: USA
Dendreon was a biotechnology company produces immunotherapy for prostate cancer. Its cancer vaccine uses a patient’s own immune cells, which are collected, processed and infused back into the individual through an intravenous infusion that is completed in three cycles.
Dendreon was a biotechnology company produces immunotherapy for prostate cancer. Its cancer vaccine uses a patient’s own immune cells, which are collected, processed and infused back into the individual through an intravenous infusion that is completed in three cycles.
13
Country: Italy
Takis main focus is the development of therapeutic cancer vaccines against tumor antigens which play a role in tumor development and maintenance.
Takis main focus is the development of therapeutic cancer vaccines against tumor antigens which play a role in tumor development and maintenance.